Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 September 2025 | Story Onthatile Tikoe | Photo Supplied
Dr Phindile Shangase
Dr Phindile Shangase, Senior Lecturer in the UFS Faculty of Health Sciences, was honoured with a Carnegie Fellowship for her impactful global public health collaboration.

The University of the Free State (UFS) is proud to announce that Dr Phindile Shangase, Senior Lecturer in the Faculty of Health Sciences and academic leader, has been selected for the highly competitive Carnegie African Diaspora Fellowship Programme (CADFP).

The CADFP links African-born academics based in the United States and Canada with universities across Africa to strengthen teaching, research, and mentorship. As part of her fellowship, Dr Shangase will host Dr Mufaro Kanyangarara, Assistant Professor at the University of South Carolina.

Reflecting on the award, Dr Shangase said, “When I received the news that I had been selected as part of the CADFP, I felt deeply honoured and humbled. The recognition affirmed not only my academic journey and professional contributions, but also the value of creating meaningful global collaborations.”

 

Collaborative project for public health impact

Dr Shangase’s project will focus on collaborative curriculum development, designed to enhance education, research, and mentorship through diaspora partnerships. The initiative aims to strengthen research skills among postgraduate students, with a particular focus on addressing the quadruple burden of disease faced by low- and middle-income countries (LMICs).

“This project will empower students to contribute to global health knowledge through impactful research and publications. It also aligns with the UFS’ strategic vision, Vision 130, which emphasises global collaboration in teaching and research,” she explained.

Dr Kanyangarara brings expertise in global health, epidemiology, and biostatistics, while Dr Shangase contributes extensive knowledge of public health teaching and the social determinants of health. Their complementary strengths will help shape the next generation of public health professionals.

 

Building capacity and global partnerships

The fellowship is expected to prepare students for leadership roles in public health, both locally and internationally. Opportunities for exchange and exposure to global collaborations will broaden their academic and professional horizons.

Looking beyond the fellowship, Dr Shangase noted that sustainability will be achieved through continued collaboration. “Dr Kanyangarara will remain involved as a collaborator in curriculum development and as a hybrid guest lecturer and research fellow. Sustainability will also be fostered through joint research initiatives, co-authored publications, and grant proposals.”

 

Advice for emerging scholars

Encouraging young academics, Dr Shangase said, “Remain steadfast in pursuing excellence while staying grounded in the unique contexts and needs of our continent. International fellowships such as the CADFP are not only about personal achievement, but also about creating meaningful impact through collaboration, mentorship, and knowledge exchange.”

Her selection reflects the UFS’ growing role as a hub for global health scholarship and its commitment to addressing pressing public health challenges through international collaboration.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept